< Back | |
17 Dec 2014 | |
The Exchange had sought clarification from Cadila Healthcare Ltd with respect to news appearing in DNA on December 17, 2014 titled "Cadila's US Arm recalls 63,648 bottles of benzonatate capsules."<BR><BR>Cadila Healthcare Ltd replied stating "the recall by our US subsidiary was voluntary and a class-III type recall, which means that the use of the product is not likely to cause any adverse health consequences. There is no material impact." | |
View all announcements for CADILA HEALTHCARE LTD. | Source: BSE India |